Alimentary pharmacology & therapeutics · 2025
CD300A+ CD8+ T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon-Alpha Therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Peng, Wang Wen-Xin, Li Jing, Lv Qiaolan, Zhu Meng-Meng, Wang You-Yuan, Zhou Ming-Ju, Chen Si-Yuan, Jiao Yan-Mei, Fan Xing, Song Jin-Wen, Xu Ruonan, Zhen Cheng, Shi Ming, Wang Fu-Sheng, Fu Junliang, Zhang Chao
Аннотация
BACKGROUND & AIMS: Pegylated interferon-alpha (PEG-IFN-α) is the first choice for achieving functional cure (FC) in chronic hepatitis B (CHB), but only about 30% of patients achieve this outcome within a defined treatment duration. Given the critical role of CD8+ T cells as antiviral effectors, we investigated their changes during FC to identify novel predictive markers of treatment efficacy.
METHODS: We enrolled CHB patients with serum HBsAg levels < 3000 IU/mL in a discovery cohort and collected their peripheral blood mononuclear cells after PEG-IFN-α therapy. We used single-cell transcriptome profiling coupled with T cell receptor (TCR) sequencing and flow cytometry to assess CD8+ T cell immune characteristics. Findings were validated longitudinally by flow cytometry in an independent cohort receiving PEG-IFN-α therapy.
RESULTS: In FC patients, CD8+ T cell subsets exhibited distinct transcriptional profiles. c04 (Temra/Teff) and c06 (proliferating T) showed significant clonal expansion compared to non-FC patients. CD300A expression was highly enriched in FC cells, correlating with cytotoxicity-related gene signatures (e.g., GZMB, GNLY, PRF1). CD300A+ CD8+ T cells demonstrated greater clonal expansion, enhanced antigen reactivity and a transcriptional network driven by TBX21 and EOMES, with enrichment of HBV-specific CD8+ T cells. Longitudinal validation confirmed that baseline CD300A+ CD8+ T cells, particularly non-naive subsets, were associated with greater HBsAg decline and earlier FC, independent of baseline HBsAg levels.
CONCLUSIONS: CD300A+ CD8+ T cells are enriched in patients achieving FC during PEG-IFN-α therapy, exhibiting robust clonal expansion, enhanced cytotoxicity and HBV antigen specificity. These cells may serve as potential biomarkers for treatment response to improve FC rates in CHB therapy.
METHODS: We enrolled CHB patients with serum HBsAg levels < 3000 IU/mL in a discovery cohort and collected their peripheral blood mononuclear cells after PEG-IFN-α therapy. We used single-cell transcriptome profiling coupled with T cell receptor (TCR) sequencing and flow cytometry to assess CD8+ T cell immune characteristics. Findings were validated longitudinally by flow cytometry in an independent cohort receiving PEG-IFN-α therapy.
RESULTS: In FC patients, CD8+ T cell subsets exhibited distinct transcriptional profiles. c04 (Temra/Teff) and c06 (proliferating T) showed significant clonal expansion compared to non-FC patients. CD300A expression was highly enriched in FC cells, correlating with cytotoxicity-related gene signatures (e.g., GZMB, GNLY, PRF1). CD300A+ CD8+ T cells demonstrated greater clonal expansion, enhanced antigen reactivity and a transcriptional network driven by TBX21 and EOMES, with enrichment of HBV-specific CD8+ T cells. Longitudinal validation confirmed that baseline CD300A+ CD8+ T cells, particularly non-naive subsets, were associated with greater HBsAg decline and earlier FC, independent of baseline HBsAg levels.
CONCLUSIONS: CD300A+ CD8+ T cells are enriched in patients achieving FC during PEG-IFN-α therapy, exhibiting robust clonal expansion, enhanced cytotoxicity and HBV antigen specificity. These cells may serve as potential biomarkers for treatment response to improve FC rates in CHB therapy.